ST. PETERSBURG, Fla., Sept. 12, 2011 /CNW/ -- The Advanced Wound Management division of Smith & Nephew (LSE: SN; NYSE: SNN) today announced the commercial launch of the PICO system - an effective, single-use, negative pressure wound therapy (NPWT) system for acute and chronic wounds, high-risk surgical incisions and skin grafts. The PICO system was officially approved by Health Canada in April 2011 and has been in preliminary use by a select group of hospitals and physicians.
The PICO system is a significant advancement in NPWT. The disposable, single-use, pump works with a revolutionary dressing technology that effectively manages fluids and eliminates the need for bulky canisters, all while being patient friendly and simple to use and operate. The PICO system can be worn for seven days and its gentle silicone wound contact layer helps minimize pain at a dressing change. With one push of the orange button, clinicians are able to use the PICO system to safely and effectively deliver NPWT to a wide range of wounds and care settings.
"As a physician, I'm always looking for ways to improve upon quality of patient care and outcomes," said Sarvesh Logsetty, MD, FRCSC, FACS, director of Manitoba Fire Fighters Burn Unit, health science centre and associate professor, plastic & general surgery at the University of Manitoba. "Therefore, I'm especially excited to have access to the new PICO system. It affords clinicians the option to treat patients who would benefit from NPWT with a simple, easy to use alternative."
The PICO system is more affordable than traditional NPWT options, and can significantly reduce related therapy costs. Available off-the-shelf, the PICO system may reduce the occurrence of delayed discharges from healthcare settings. The PICO system may also reduce the occurrence of surgical site complications and associated costs, time needed to care for a wound and the risk of re-admission.
"The PICO system showcases Smith & Nephew's commitment to reducing the human and economic cost of wounds by providing a treatment option that is both affordable and easy for people to incorporate into their daily lives," said Thomas Dugan, president, advanced wound management, Americas. "The Canadian marketplace offers Smith & Nephew the opportunity to expand the PICO system to patients who may benefit from its innovative technology at a more affordable price compared to traditional NPWT."
To further enhance the customer experience, the Smith & Nephew Sales Force will use a custom-developed iPad application to introduce the PICO system. The application is designed to be an interactive experience that includes video, product animations, testimonials, case studies and product information. A mobile enabled website will allow patients and clinicians to access information about the PICO system when they are on the go. PICO packaging and advertising will include an MS Tag that will link to an application/mechanism of action video, eliminating the need for complex training modules. Clinicians and patients can also refer to the Customer Action Centre at 800-462-7439, for more information about the NPWT portfolio of products from Smith & Nephew.
For more information about the PICO system, please visit www.possiblewithpico.com. To get the latest and timeliest news from the Advanced Wound Management division of Smith & Nephew, register at www.Twitter.com today and "follow" @woundcare.
About Smith & Nephew
Smith & Nephew is a global medical technology business with global leadership positions in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy, including Sports Medicine; and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.
Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company has distribution channels, purchasing agents and buying entities in over 90 countries worldwide. Annual sales in 2010 were nearly $4.0 billion.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions and our success in integrating acquired businesses; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE The Advanced Wound Management division of Smith
For further information: Analyst/Investor, Phil Cowdy of Smith & Nephew, +44 (0) 20 7401 7646; or Media, Mary Coyle of Ogilvy Public Relations Worldwide, +1-212-880-5258, Mary.Coyle@ogilvy.com, for Smith & Nephew; or Thomas J. Dugan, President, Advanced Wound Management, Americas of Smith & Nephew, +1-727-399-3766